Two M&A deals and $9B later, Lonnie Moulder is ramping up his latest biotech startup. And this one comes with global vision built in.

Mar 23, 2021

Lonnie Moulder may have been in silent running mode in the 2 years since he closed the $5 billion sale of Tesaro to GlaxoSmithKline. But he hasn’t been idle.

Today during the China Healthcare Investment Conference in Shanghai, Moulder’s taking the wraps off a biotech startup he’s put together that has assembled a pipeline with 7 drugs in it, a plan to add several more therapies and a quick vault into the clinic for a company with a small but fast-expanding team that is growing roots in China and the US.

Read more >